论文部分内容阅读
钙阻滞剂治疗继发性肺动脉高压(Secondary Pulmonary Hypertension,SPH)是80年代新课题。虽然多数学者认为硝苯吡啶等用于慢性阻滞性肺病(COPD)具较肯定疗效,但仍有不少分歧意见,现介绍如下。一、SPH的病理特征最近的研究提示,SPH1/3归咎于肺血管痉挛,1/3原于组织结构改变,另1/3则与红细胞增多症有关。 SPH指肺实质病变引起的肺动脉高压,多与COPD有关。缺氧是SPH发生的关键机制,动物实验证实肺动脉压升高与体循环动脉血氧饱和度成比例。
Calcium blockers in the treatment of secondary pulmonary hypertension (Secondary Pulmonary Hypertension, SPH) is a new topic in the 1980s. Although most scholars believe that nifedipine and other chronic obstructive pulmonary disease (COPD) with a more positive effect, but there are still many differences of opinion, are presented below. First, the pathological features of SPH Recent studies suggest that SPH1 / 3 attributed to pulmonary vasospasm, 1/3 of the original organizational structure changes, and the other 1/3 and polycythemia. SPH refers to pulmonary hypertension caused by pulmonary hypertension, mostly associated with COPD. Hypoxia is a key mechanism for the development of SPH. Animal experiments confirm that pulmonary hypertension is proportional to systemic arterial oxygen saturation.